Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq:…
RadNet, Inc. to Present at the Raymond James 47th Annual Institutional Investors Conference on Tuesday, March 3rd, 2026
March 02, 2026 13:16 ET | Source: RadNet, Inc. LOS ANGELES, March…
Smith+Nephew to feature leading rotator cuff repair portfolio including new Tendon Seam Repair System and REGENETEN Bioinductive Implant at AAOS 2026
Uniting the most advanced technologies for biomechanical repair and biological augmentation Smith+Nephew…
Pediatric Home Service Partners with Morgans to Expand Prescribed Pediatric Extended Care Services in Texas with New Center, Morgans Wonder Care
SAN ANTONIO, March 02, 2026 (GLOBE NEWSWIRE) -- Pediatric Home Service (PHS),…
First Large-Scale Study by AI Search Monitoring Platform OtterlyAI Shows YouTube is #2 Social Platform for AI Citations
First analysis of 100 million AI citations across six platforms shows AI…
Wix Launches App in ChatGPT, Expanding Website Creation to one of the Worlds Leading Conversational AI Platforms
Users can now generate Wix Harmony websites directly within their ChatGPT conversations…
Verum Messenger Launched Its Own Payment System – Verum Finance
The new functionality expands the capabilities of the messenger, transforming it into…
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
-- -18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142)…
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease
March 01, 2026 09:45 ET | Source: Celldex Therapeutics, Inc. - Late…
